Edition:
United States

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

88.15USD
22 Mar 2019
Change (% chg)

$-1.48 (-1.65%)
Prev Close
$89.63
Open
$89.22
Day's High
$89.49
Day's Low
$87.96
Volume
2,681,686
Avg. Vol
2,937,080
52-wk High
$95.30
52-wk Low
$58.61

Latest Key Developments (Source: Significant Developments)

Bristol-Myers Squibb Co - Urges Shareholders To Vote "For" Proposed Celgene Transaction On White Proxy Card
Tuesday, 19 Mar 2019 06:59am EDT 

March 19 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB FILES INVESTOR PRESENTATION HIGHLIGHTING SIGNIFICANT BENEFITS OF PENDING TRANSACTION WITH CELGENE.BRISTOL-MYERS SQUIBB CO - URGES SHAREHOLDERS TO VOTE "FOR" PROPOSED CELGENE TRANSACTION ON WHITE PROXY CARD.  Full Article

Allergan PLC - Robert J. Hugin Appointed To Allergan Board Of Directors
Tuesday, 19 Feb 2019 07:00am EST 

Feb 19 (Reuters) - Allergan plc ::ROBERT J. HUGIN APPOINTED TO ALLERGAN BOARD OF DIRECTORS.ALLERGAN PLC - COMPANY TO RECOMMEND FOR A SHAREHOLDER PROPOSAL TO PHASE IN INDEPENDENT BOARD CHAIR AT NEXT LEADERSHIP TRANSITION.ALLERGAN PLC - HUGIN WAS FORMERLY CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF CELGENE CORPORATION.  Full Article

Obsidian Therapeutics Announces Strategic Collaboration With Celgene
Friday, 18 Jan 2019 07:00am EST 

Jan 18 (Reuters) - Celgene Corp ::OBSIDIAN THERAPEUTICS ANNOUNCES STRATEGIC COLLABORATION WITH CELGENE TO DEVELOP NOVEL CELL THERAPIES WITH TUNABLE IMMUNOMODULATORY FACTORS, OPENING POTENTIAL FOR CAR-T AND OTHER CELLULAR MEDICINES IN NEW SETTINGS.OBSIDIAN THERAPEUTICS SAYS COLLABORATION INCLUDES AN UPFRONT PAYMENT AND EQUITY INVESTMENT BY CELGENE.OBSIDIAN THERAPEUTICS SAYS COLLABORATION INCLUDES POTENTIAL FUTURE MILESTONE AND ROYALTY PAYMENTS BY CELGENE.OBSIDIAN THERAPEUTICS- ENTER INTO MULTI-YEAR STRATEGIC COLLABORATION WITH CELGENE RECEIVING EXCLUSIVE OPTIONS TO LICENSE CELL THERAPIES.OBSIDIAN - DEAL GIVES CELGENE EXCLUSIVE OPTION TO IN-LICENSE WORLDWIDE RIGHTS FOR CELL THERAPY CANDIDATES THAT INCORPORATE DD-REGULATED IL12 OR CD40L.  Full Article

Biond Biologics Announces $17 Mln Series B Financing
Tuesday, 8 Jan 2019 07:00am EST 

Jan 8 (Reuters) - Celgene Corp ::BIOND BIOLOGICS ANNOUNCES $17 MILLION SERIES B FINANCING.BIOND BIOLOGICS - FINANCING AND DUE DILIGENCE LED BY ISRAEL BIOTECH FUND, HAREL INSURANCE & FINANCE GROUP, WITH PARTICIPATION OF CELGENE, OTHERS.  Full Article

Nantcell Announces New Celgene Investment
Friday, 4 Jan 2019 07:01pm EST 

Jan 4 (Reuters) - Celgene Corp ::NANTCELL ANNOUNCES NEW CELGENE INVESTMENT.NANTCELL SAYS SECOND ROUND CROSSOVER FUNDING BRINGS CELGENE'S INVESTMENT TO $105M IN NANTCELL VALUED AT $4 BILLION.  Full Article

Celgene Says $33.5 Bln Fully Underwritten Bridge Facility Obtained From Morgan Stanley And MUFG For Financing Bristol-Myers Squibb Deal
Thursday, 3 Jan 2019 07:06am EST 

Jan 3 (Reuters) - Bristol-Myers Squibb Co ::CELGENE SAYS $33.5 BILLION FULLY UNDERWRITTEN BRIDGE FACILITY OBTAINED FROM MORGAN STANLEY AND MUFG FOR FINANCING BRISTOL-MYERS SQUIBB DEAL - PRESENTATION.  Full Article

Dragonfly Therapeutics announces expansion of its strategic collaboration with Celgene, doubling the number of programs and including targets for solid tumor indications
Wednesday, 14 Nov 2018 08:00am EST 

Nov 14 (Reuters) - Celgene Corp ::DRAGONFLY THERAPEUTICS ANNOUNCES EXPANSION OF ITS STRATEGIC COLLABORATION WITH CELGENE, DOUBLING THE NUMBER OF PROGRAMS AND INCLUDING TARGETS FOR SOLID TUMOR INDICATIONS.CELGENE - DEAL TO LICENSE INTELLECTUAL PROPERTY RIGHTS TO PRODUCTS DEVELOPED USING DRAGONFLY'S TRINKET TECHNOLOGY PLATFORM FOR A $50 MILLION UPFRONT FEE.  Full Article

Temasek Holdings Dissolves Share Stake In Medtronic, Celgene
Wednesday, 14 Nov 2018 06:37am EST 

Nov 14 (Reuters) - Temasek Holdings (Private) Ltd::TEMASEK HOLDINGS (PRIVATE) LTD DISSOLVES SHARE STAKE IN MEDTRONIC PLC.TEMASEK HOLDINGS (PRIVATE) LTD DISSOLVES SHARE STAKE IN CELGENE CORP - SEC FILING.TEMASEK HOLDINGS (PRIVATE) LTD CUTS SHARE STAKE IN JD.COM BY 27.2 PERCENT TO 5.3 MILLION CLASS A SPONSORED ADRS.TEMASEK HOLDINGS (PRIVATE) LTD TAKES SHARE STAKE OF 596,946 SPONSORED ADRS IN BP PLC.TEMASEK HOLDINGS (PRIVATE) LTD UPS SHARE STAKE IN AC IMMUNE SA BY 95.4 PERCENT TO 2.6 MILLION SHARES.TEMASEK HOLDINGS (PRIVATE) LTD - CHANGE IN HOLDINGS ARE AS OF SEPTEMBER 30, 2018 AND COMPARED WITH THE PREVIOUS QUARTER ENDED AS OF JUNE 30, 2018.  Full Article

Oncomed Provides Update On Navicixizumab Partnership
Thursday, 20 Sep 2018 08:00am EDT 

Sept 20 (Reuters) - OncoMed Pharmaceuticals Inc ::ONCOMED PROVIDES UPDATE ON NAVICIXIZUMAB PARTNERSHIP.ONCOMED PHARMACEUTICALS - CELGENE NOTIFIED CO IT DECIDED NOT TO EXERCISE ITS OPTION TO LICENSE CO'S BISPECIFIC ANTIBODY NAVICIXIZUMAB.ONCOMED PHARMACEUTICALS INC - ONCOMED AND CELGENE ARE WORKING TO FORMALIZE TERMINATION OF COLLABORATION AGREEMENT WITH RESPECT TO NAVICIXIZUMAB.ONCOMED PHARMACEUTICALS - CELGENE CONTINUES TO RETAIN ITS OPTIONS TO LICENSE ONCOMED'S ETIGILIMAB UNDER COLLABORATION.ONCOMED PHARMACEUTICALS INC - EXPECTS TO RETAIN WORLDWIDE RIGHTS TO NAVICIXIZUMAB.ONCOMED PHARMACEUTICALS INC - ONCOMED EXPECTS TO RETAIN WORLDWIDE RIGHTS TO NAVICIXIZUMAB.  Full Article

Evotec, Celgene Partner On Targeted Protein Degradation
Thursday, 6 Sep 2018 01:00am EDT 

Sept 6 (Reuters) - Evotec AG ::DGAP-NEWS: EVOTEC AND CELGENE ENTER PARTNERSHIP IN THE FIELD OF TARGETED PROTEIN DEGRADATION.SAYS FINANCIALS INCLUDE UPFRONT PAYMENT AS WELL AS SIGNIFICANT POTENTIAL MILESTONE-BASED PAYMENTS AND ROYALTIE.  Full Article

U.S. court rejects Alvogen's patent challenge for Celgene's cancer drug

The U.S. patent office on Thursday rejected a filing by Alvogen Pine Brook Llc for a review challenging patents on Celgene Corp's blockbuster myeloma drug Revlimid.